Gout is the most common form of inflammatory arthritis, characterized by painful and disabling acute attacks. It is caused by hyperuricemia and the deposition of urate crystals in and around the joints. Long-standing untreated hyperuricemia can lead to chronic arthritis, joint damage, tophi formation, and urate nephropathy. According to the Australian Bureau of Statistics and National Health Survey 2017-2018, it is estimated that 187,000 Australians (0.8% of the population) suffer from gout conditions. Gout is more common in males than females. Almost 9 in 10 (87%) people with gout are males. Hence, gout treatment demand is increasing, which is expected to show growth over the forecast period.
NSAIDs, corticosteroids, and colchicine are majorly used to treat acute gout. The non-steroidal anti-inflammatory drugs (NSAIDs) are estimated to dominate the gout therapeutics market in 2019, owing to the availability of these drugs at a lower cost compared to other drugs, the high level of penetration of drugs, and the ability to relieve pain in case of an acute gout attack. NSAIDs decrease pain and swelling. Some NSAIDs are available over-the-counter, like ibuprofen and naproxen sodium. The doctor prescribes stronger NSAIDs like indomethacin and celecoxib.
Market Dynamics
Drivers
- Increasing incidences of gout therapeutics
- The rising burden of gout therapeutics with the increasing geriatric population
- Growing adoption of biologics and increasing R&D on regenerative medicines
Restraints
- Side Effects of Gout Therapeutic Drugs
Market Segmentation
The non-steroidal anti-inflammatory drugs (NSAIDs) drug class segment was valued at US$ 1,053.8 million in 2018 and is estimated to reach US$ 1,987.9 million by 2027, growing at a CAGR of 7.3 % during the forecast period (2020-2027).
The non-steroidal anti-inflammatory drugs (NSAIDs) are estimated to dominate the gout therapeutics market in 2019, owing to the availability of these drugs at a lower cost compared to other drugs, the high level of penetration of drugs, and the ability to relieve pain in case of an acute gout attack. NSAIDs are the first-line drugs used to decrease the inflammation and the associated pain of rheumatic and non-rheumatic diseases. The rising number of gout patients, low cost of drugs, and application in combination therapy are likely to drive the market. Indomethacin and naproxen are major choices for the acute attack of gout. NSAIDs decrease pain and swelling. Some NSAIDs are available over-the-counter, like ibuprofen and naproxen sodium. The doctor prescribes stronger NSAIDs like indomethacin and celecoxib. Although NSAID effects on pain tend to be patient-specific, naproxen and indomethacin are common choices. Use of concomitant gastric protection with misoprostol or a cyclooxygenase-2 (COX-2)–specific NSAID might be considered if the patient has gastrointestinal (GI) risk older than 51 years. To control the attack as quickly and safely as possible (recalling that it takes 5 half-lives to reach a steady-state), NSAID with a short half-life (e.g., ketoprofen, ibuprofen, or diclofenac) are preferred.
Geographical Analysis
North America is dominating the global gout therapeutics market, accounting for the largest market share in 2019, owing to the large presence of major players, high demand for gout therapy, and high cost of branded pharmaceuticals U.S. Also, the research and development of new drugs for gout treatment is expected to show dominance over the forecast period. In June 2020, Pharma major Dr. Reddy's Laboratories launched the generic Colchicine tablets to prevent and treat acute gout flares in the US market.
In December 2019, Selecta Biosciences, Inc., a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, completed the patient enrollment in the six-month, head-to-head, Phase 2 COMPARE clinical trial. The trial evaluates the superiority of a once-monthly dose of Selecta’s lead product candidate, SEL-212 (ImmTOR + pegadricase), versus a bi-weekly dose of pegloticase, the current FDA-approved uricase therapy for adult patients with chronic refractory gout.
As per a recent research report published by National Health and Nutrition Examination Survey (NHANES), the prevalence of gout among adults in the US is around 3.9%, affecting nearly 8.3 million people across the nation. Such a high number of patients is thus the chief driving factor for developing the gout therapeutics market. The prevalence of gout is higher in African Americans than Caucasians, increasing prevalence across all demographics.
For instance, according to the Partnership to Fight Chronic Disease (PFCD) survey report, in the United States, the prevalence rate of gout was increased from 0.78% in 2000 to 1.51% in 2015. Moreover, in 2017 the prevalence rate was 1489.73 (per 100,000 population). Thus, rising prevalence of gout and considering the association between alcohol consumption and gout, it can be expected that increasing alcohol consumption will act as a driver for the growth of the gout therapeutics market in the region.
About Us:
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at DataM Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com
